Dashboard

Beam Therapeutics, Inc. (BEAM)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

B

Management & Equity

B

Analyst Opinion

H

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

CEO

John Evans

Employees

118

Industry

Diversified Biopharmaceuticals

Sector

Healthcare

Headquarters

Cambridge

Exchange

NASDAQ

Summary Stats

Market Cap

2.29B

Revenue

60.3M

Net Income

-238M

EPS

-$3.59

Price-to-Earnings

-9.07

Price-to-Book

2.76

Debt-to-Equity

0.75

News

Analyst Ratings

Price targets projected by 4 analysts

High

$47.00

Average

$43.00

Low

$38.00

Ratings calculated by 5 analysts

Buy

5

Hold

0

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q1 2022

Last Earnings

Above by $0.31

Actual

-$1.01 +23.5%

Consensus

-1.32

Report Date

Year Ago

-3.35

Year Ago Change %

Up 69%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites